AEON — Aeon Biopharma Income Statement
0.000.00%
- $10.01m
- $24.65m
Annual income statement for Aeon Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K/A |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Total Revenue | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Unusual Expense / Income | |||
Other Operating Expenses | |||
Total Operating Expenses | 56.3 | 48.4 | 348 |
Operating Profit | -56.3 | -48.4 | -348 |
Total Net Non Operating Interest Income / Expense | |||
Other Net Non Operating Costs | |||
Net Income Before Taxes | -55.6 | -52.6 | -385 |
Provision for Income Taxes | |||
Net Income After Taxes | -55.6 | -52.6 | -385 |
Net Income Before Extraordinary Items | |||
Net Income | -55.6 | -52.6 | -385 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | -55.6 | -52.6 | -385 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | -0.975 | -1.41 | -0.986 |